| Dry Eye Syndromes
Tyrvaya vs Eysuvis
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Tyrvaya vs Eysuvis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEysuvis has a higher rate of injection site reactions vs Tyrvaya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eysuvis but not Tyrvaya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tyrvaya
Eysuvis
At A Glance
Nasal spray
Twice daily
Nicotinic acetylcholine receptor agonist
Ophthalmic
Four times daily
Corticosteroid
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes One spray in each nostril twice daily, approximately 12 hours apart; prime with 7 actuations before initial use and re-prime with 1 actuation if not used for more than 5 days.
Dry Eye Syndromes Instill one to two drops into each eye four times daily for up to two weeks.
Contraindications
—
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
Adverse Reactions
Most common (>=5%) sneezing (82%), cough (16%), throat irritation (13%), instillation-site (nose) irritation (8%)
Most common (>=5%) Instillation site pain
Serious Elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing, secondary ocular infection from pathogens including herpes simplex, perforation of the globe
Pharmacology
Nicotinic acetylcholine receptor agonist; varenicline binds heteromeric nACh receptor subtypes (alpha4beta2, alpha4alpha6beta2, alpha3beta4, alpha3alpha5beta4) and the alpha7 receptor, activating the trigeminal parasympathetic pathway to increase basal tear film production in dry eye disease.
Corticosteroid that inhibits the inflammatory response by suppressing edema, fibrin deposition, capillary dilation, leukocyte migration, fibroblast proliferation, and collagen deposition, likely via inhibition of prostaglandin production through glucocorticoid receptor binding.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tyrvaya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Eysuvis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
UnitedHealthcare
Tyrvaya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Eysuvis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Tyrvaya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Eysuvis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tyrvaya.
No savings programs available for Eysuvis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TyrvayaView full Tyrvaya profile
EysuvisView full Eysuvis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.